AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019

Nov 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2019-11-12

Reporting Person: CELGENE CORP /DE/ (10% Owner)
Reporting Person: Celgene European Investment Co LLC (10% Owner)
Reporting Person: Celgene Switzerland LLC (10% Owner)
Reporting Person: Celgene Alpine Investment Co., LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-12	Common Stock	P	403225	$31.00	Acquired	1777824	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	624575	Indirect
Common Stock	4010926	Indirect
Common Stock	708333	Indirect

Footnotes

F1: Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.